| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| In Thousands, except per share data | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net sales | $ | 213,810 | $ | 162,639 | $ | 338,879 | $ | 234,669 | |||||||||||||||
| Cost of goods sold | 95,942 | 61,143 | 170,224 | 105,020 | |||||||||||||||||||
| Gross profit | 117,868 | 101,496 | 168,655 | 129,649 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Selling, general and administrative expense | 26,993 | 15,967 | 50,054 | 32,266 | |||||||||||||||||||
| Amortization expense | 24,025 | 14,604 | 46,624 | 28,703 | |||||||||||||||||||
| Founders advisory fees - related party | 266,255 | 96,883 | 189,877 | 16,270 | |||||||||||||||||||
| Other operating expense | 3,614 | 268 | 12,632 | 829 | |||||||||||||||||||
| Total operating expenses | 320,887 | 127,722 | 299,187 | 78,068 | |||||||||||||||||||
| Operating (loss) income | (203,019) | (26,226) | (130,532) | 51,581 | |||||||||||||||||||
| Other expense (income): | |||||||||||||||||||||||
| Interest expense, net | 19,593 | 9,930 | 43,949 | 19,574 | |||||||||||||||||||
| Foreign currency gain | (1,203) | (2,096) | (2,554) | (3,255) | |||||||||||||||||||
| Other expense (income), net | 27 | (212) | (337) | (69) | |||||||||||||||||||
| Total other expense, net | 18,417 | 7,622 | 41,058 | 16,250 | |||||||||||||||||||
| (Loss) income before income taxes | (221,436) | (33,848) | (171,590) | 35,331 | |||||||||||||||||||
| Income tax benefit (expense) | 39,801 | 1,687 | 62,891 | (10,806) | |||||||||||||||||||
| Net (loss) income | (181,635) | (32,161) | (108,699) | 24,525 | |||||||||||||||||||
| Other comprehensive (loss) income, net of tax: | |||||||||||||||||||||||
| Foreign currency translation adjustments | (9,132) | 24,120 | (15,698) | 32,005 | |||||||||||||||||||
| Total comprehensive (loss) income | $ | (190,767) | $ | (8,041) | $ | (124,397) | $ | 56,530 | |||||||||||||||
| (Loss) earnings per share: | |||||||||||||||||||||||
| Basic | $ | (1.11) | $ | (0.22) | $ | (0.69) | $ | 0.17 | |||||||||||||||
| Diluted | $ | (1.11) | $ | (0.22) | $ | (0.69) | $ | 0.16 | |||||||||||||||
| Weighted average number of shares outstanding: | |||||||||||||||||||||||
| Basic | 163,410,894 | 147,055,804 | 158,663,642 | 147,779,470 | |||||||||||||||||||
| Diluted | 163,410,894 | 147,055,804 | 158,663,642 | 156,039,133 | |||||||||||||||||||
| In Thousands, except per share data | June 30, 2026 | December 31, 2025 | |||||||||
| ASSETS | (Unaudited) | ||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 82,776 | $ | 325,927 | |||||||
| Accounts receivable, net | 158,095 | 64,363 | |||||||||
| Inventories | 203,265 | 139,634 | |||||||||
| Prepaid expenses and other current assets | 52,252 | 34,049 | |||||||||
| Total current assets | 496,388 | 563,973 | |||||||||
| Property, plant and equipment, net | 109,215 | 85,138 | |||||||||
| Operating lease right-of-use assets | 41,351 | 30,152 | |||||||||
| Finance lease right-of-use assets | 5,223 | 5,713 | |||||||||
| Goodwill | 1,365,724 | 1,065,211 | |||||||||
| Customer lists, net | 904,934 | 628,189 | |||||||||
| Technology and patents, net | 195,537 | 184,804 | |||||||||
| Tradenames, net | 123,064 | 86,330 | |||||||||
| Other assets, net | 3,322 | 3,497 | |||||||||
| Total assets | $ | 3,244,758 | $ | 2,653,007 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 44,967 | $ | 30,301 | |||||||
| Accrued expenses and other current liabilities | 67,062 | 47,212 | |||||||||
| Founders advisory fees payable - related party | 177,957 | 95,726 | |||||||||
| Deferred revenue | 26,413 | 1,879 | |||||||||
| Total current liabilities | 316,399 | 175,118 | |||||||||
| Long-term debt, net | 1,210,247 | 669,122 | |||||||||
| Operating lease liabilities, net of current portion | 36,370 | 27,860 | |||||||||
| Finance lease liabilities, net of current portion | 5,367 | 5,694 | |||||||||
| Deferred income taxes | 77,997 | 80,410 | |||||||||
| Founders advisory fees payable - related party | 452,617 | 440,697 | |||||||||
| Preferred stock | 118,962 | 115,904 | |||||||||
| Preferred stock - related party | 520 | 1,293 | |||||||||
| Other non-current liabilities | 4,661 | 3,590 | |||||||||
| Total liabilities | 2,223,140 | 1,519,688 | |||||||||
| Equity: | |||||||||||
| Common stock, $0.0001 par value per share | 19 | 17 | |||||||||
| Treasury stock, at cost | (168,197) | (168,197) | |||||||||
| Additional paid-in capital | 2,113,652 | 2,100,958 | |||||||||
| Accumulated other comprehensive loss | (22,068) | (6,370) | |||||||||
| Accumulated deficit | (901,788) | (793,089) | |||||||||
| Total equity | 1,021,618 | 1,133,319 | |||||||||
| Total liabilities and equity | $ | 3,244,758 | $ | 2,653,007 | |||||||
| Six Months Ended June 30, | |||||||||||
| In Thousands | 2026 | 2025 | |||||||||
| Cash flows from operating activities: | |||||||||||
| Net (loss) income | $ | (108,699) | $ | 24,525 | |||||||
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | |||||||||||
| Founders advisory fees - related party (change in fair value) | 189,877 | 16,270 | |||||||||
| Depreciation and amortization expense | 56,047 | 34,817 | |||||||||
| Interest and payment-in-kind on preferred stock | 3,809 | 3,666 | |||||||||
| Stock-based compensation | 5,490 | 4,909 | |||||||||
| Non-cash lease expense | 5,283 | 2,913 | |||||||||
| Deferred income taxes | (73,319) | (11,293) | |||||||||
| Amortization of deferred financing costs | 1,347 | 890 | |||||||||
| Foreign currency gain | (2,554) | (3,255) | |||||||||
| Loss on disposal of assets | 17 | 6 | |||||||||
| Changes in operating assets and liabilities, net of acquisitions: | |||||||||||
| Accounts receivable | (69,451) | (63,460) | |||||||||
| Inventories | (15,856) | (21,834) | |||||||||
| Prepaid expenses and current other assets | (21,335) | 4,687 | |||||||||
| Accounts payable | 7,281 | 12,003 | |||||||||
| Deferred revenue | 23,275 | 18,340 | |||||||||
| Income taxes payable, net | 2,721 | 7,962 | |||||||||
| Accrued expenses and other current liabilities | 5,105 | (763) | |||||||||
| Founders advisory fees - related party (cash settled) | (95,726) | (6,677) | |||||||||
| Operating lease liabilities | (4,085) | (1,998) | |||||||||
| Finance lease liabilities | (236) | (251) | |||||||||
| Other, net | 1,394 | (563) | |||||||||
| Net cash (used in) provided by operating activities | (89,615) | 20,894 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchase of property and equipment | (18,526) | (17,577) | |||||||||
| Purchase of intangible assets | — | (15,226) | |||||||||
| Purchase of businesses, net of cash acquired | (682,294) | (10,000) | |||||||||
| Net cash used in investing activities | (700,820) | (42,803) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Common stock repurchased | — | (40,370) | |||||||||
| Proceeds from exercises of options | 7,648 | 292 | |||||||||
| Principal payments on finance lease obligations | (379) | (482) | |||||||||
| Proceeds from issuance of long-term debt | 550,000 | — | |||||||||
| Payment of debt issuance costs | (10,057) | — | |||||||||
| Net cash provided by (used in) financing activities | 547,212 | (40,560) | |||||||||
| Effect of foreign currency on cash and cash equivalents | 72 | 4,671 | |||||||||
| Net change in cash and cash equivalents | (243,151) | (57,798) | |||||||||
| Cash and cash equivalents, beginning of period | 325,927 | 198,456 | |||||||||
| Cash and cash equivalents, end of period | $ | 82,776 | $ | 140,658 | |||||||
| Supplemental disclosures of cash flow information: | |||||||||||
| Cash paid for interest | $ | 19,573 | $ | 19,698 | |||||||
| Cash paid for income taxes | $ | 5,647 | $ | 12,844 | |||||||
| (Unaudited) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | |||||||||||||||||||||||||||||||||
| In Thousands | Fire Safety | Specialty Products | Total | Fire Safety | Specialty Products | Total | |||||||||||||||||||||||||||||
| Loss before income taxes | $ | (179,329) | $ | (42,107) | $ | (221,436) | $ | (27,068) | $ | (6,780) | $ | (33,848) | |||||||||||||||||||||||
| Depreciation and amortization | 14,258 | 14,650 | 28,908 | 13,620 | 4,304 | 17,924 | |||||||||||||||||||||||||||||
| Interest and financing expense | 8,594 | 10,999 | 19,593 | 6,180 | 3,750 | 9,930 | |||||||||||||||||||||||||||||
| Founders advisory fees - related party | 233,180 | 33,075 | 266,255 | 83,319 | 13,564 | 96,883 | |||||||||||||||||||||||||||||
Non-recurring expenses (1) | 1,217 | 1,326 | 2,543 | 27 | 13 | 40 | |||||||||||||||||||||||||||||
| Acquisition costs | — | 3,558 | 3,558 | 96 | 171 | 267 | |||||||||||||||||||||||||||||
| Stock-based compensation expense | 2,009 | 883 | 2,892 | 2,007 | 231 | 2,238 | |||||||||||||||||||||||||||||
Purchase accounting impact - inventory step up (2) | — | 4,480 | 4,480 | — | — | — | |||||||||||||||||||||||||||||
| Foreign currency (gain) loss | (1,170) | (33) | (1,203) | (522) | (1,574) | (2,096) | |||||||||||||||||||||||||||||
| Segment Adjusted EBITDA | $ | 78,759 | $ | 26,831 | $ | 105,590 | $ | 77,659 | $ | 13,679 | $ | 91,338 | |||||||||||||||||||||||
| (1) | For the three months ended June 30, 2026, $1.4 million was related to restructuring and other non-recurring costs and $1.1 million was related to litigation costs arising from a contractual dispute regarding control of the P2S5 facility, which is currently operated by Flexsys Chemical Company. For the three months ended June 30, 2025, $0.1 million was related to restructuring and other non-recurring costs. | ||||
| (2) | For the three months ended June 30, 2026, $4.5 million was primarily related to the impact of purchase accounting on the cost of inventory sold. The acquired inventory was recorded at fair value, resulting in a step-up in basis. | ||||
| (Unaudited) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | |||||||||||||||||||||||||||||||||
| In Thousands | Fire Safety | Specialty Products | Total | Fire Safety | Specialty Products | Total | |||||||||||||||||||||||||||||
| (Loss) income before income taxes | $ | (117,202) | $ | (54,388) | $ | (171,590) | $ | 31,810 | $ | 3,521 | $ | 35,331 | |||||||||||||||||||||||
| Depreciation and amortization | 28,750 | 27,297 | 56,047 | 26,385 | 8,432 | 34,817 | |||||||||||||||||||||||||||||
| Interest and financing expense | 19,049 | 24,900 | 43,949 | 12,134 | 7,440 | 19,574 | |||||||||||||||||||||||||||||
| Founders advisory fees - related party | 166,290 | 23,587 | 189,877 | 13,992 | 2,278 | 16,270 | |||||||||||||||||||||||||||||
Non-recurring expenses (1) | 1,349 | 1,585 | 2,934 | 261 | 686 | 947 | |||||||||||||||||||||||||||||
| Acquisition costs | 10 | 12,516 | 12,526 | 96 | 732 | 828 | |||||||||||||||||||||||||||||
| Stock-based compensation expense | 2,725 | 2,765 | 5,490 | 3,583 | 1,326 | 4,909 | |||||||||||||||||||||||||||||
Purchase accounting impact - inventory step up (2) | — | 10,070 | 10,070 | — | — | — | |||||||||||||||||||||||||||||
| Foreign currency (gain) loss | (3,521) | 967 | (2,554) | (517) | (2,738) | (3,255) | |||||||||||||||||||||||||||||
| Segment Adjusted EBITDA | $ | 97,450 | $ | 49,299 | $ | 146,749 | $ | 87,744 | $ | 21,677 | $ | 109,421 | |||||||||||||||||||||||
| (1) | For the six months ended June 30, 2026, $1.5 million was related to restructuring and other non-recurring costs and $1.4 million was related to litigation costs arising from a contractual dispute regarding control of the P2S5 facility, which is currently operated by Flexsys Chemical Company. For the six months ended June 30, 2025, $0.6 million was related to restructuring and other non-recurring costs and $0.4 million was related to the Redomiciliation Transaction. | ||||
| (2) | For the six months ended June 30, 2026, $10.1 million was primarily related to the impact of purchase accounting on the cost of inventory sold. The acquired inventory was recorded at fair value, resulting in a step-up in basis. | ||||
| (Unaudited) | Three Months Ended June 30, | ||||||||||||||||
| In Thousands, except share and per share data | 2026 | 2025 | |||||||||||||||
| GAAP net loss | $ | (181,635) | $ | (32,161) | |||||||||||||
| Adjustments: | |||||||||||||||||
| Amortization | 24,025 | 14,604 | |||||||||||||||
| Founders advisory fees - related party | 266,255 | 96,883 | |||||||||||||||
Non-recurring expenses (1) | 2,543 | 40 | |||||||||||||||
| Acquisition costs | 3,558 | 267 | |||||||||||||||
| Stock-based compensation expense | 2,892 | 2,238 | |||||||||||||||
Purchase accounting impact - inventory step up (2) | 4,480 | — | |||||||||||||||
| Foreign currency gain | (1,203) | (2,096) | |||||||||||||||
Tax impact of non-GAAP adjustments (3) | (61,344) | (22,631) | |||||||||||||||
| Adjusted net income | $ | 59,571 | $ | 57,144 | |||||||||||||
| Shares used in computing GAAP Earnings (Loss) Per Share (diluted) | 163,410,894 | 147,055,804 | |||||||||||||||
Options (4) | 7,723,977 | 1,276,730 | |||||||||||||||
Shares underlying Founders fixed advisory fees (5) | — | — | |||||||||||||||
Shares underlying Founders variable advisory fees (6) | — | — | |||||||||||||||
| Shares used in computing Adjusted Earnings Per Share (diluted) | 171,134,871 | 148,332,534 | |||||||||||||||
| GAAP (Loss) Earnings Per Share (diluted) | $ | (1.11) | $ | (0.22) | |||||||||||||
| Adjusted Earnings Per Share (diluted) | $ | 0.35 | $ | 0.39 | |||||||||||||
| ______________________________ | |||||||||||||||||
| (1) | For the three months ended June 30, 2026, $1.4 million was related to restructuring and other non-recurring costs and $1.1 million was related to litigation costs arising from a contractual dispute regarding control of the P2S5 facility, which is currently operated by Flexsys Chemical Company. For the three months ended June 30, 2025, $0.1 million was related to restructuring and other non-recurring costs. | ||||||||||||||||
| (2) | For the three months ended June 30, 2026, $4.5 million was primarily related to the impact of purchase accounting on the cost of inventory sold. The acquired inventory was recorded at fair value, resulting in a step-up in basis. | ||||||||||||||||
| (3) | The tax impact of non-GAAP adjustments reflects the total income tax expense commensurate with the non-GAAP measure of profitability. | ||||||||||||||||
| (4) | The Company adds back the dilutive impact of options if amounts were excluded for purposes of GAAP EPS due to a GAAP net loss during the period. | ||||||||||||||||
| (5) | As of June 30, 2026, a maximum of 2.4 million shares were issuable within 12 months under the Founders fixed advisory fee. | ||||||||||||||||
| (6) | Based on period end market prices as of June 30, 2026, a maximum of 6.1 million shares were issuable within 12 months under the Founders variable advisory fee. | ||||||||||||||||
| (Unaudited) | Six Months Ended June 30, | ||||||||||||||||
| In Thousands, except share and per share data | 2026 | 2025 | |||||||||||||||
| GAAP net (loss) income | $ | (108,699) | $ | 24,525 | |||||||||||||
| Adjustments: | |||||||||||||||||
| Amortization | 46,624 | 28,703 | |||||||||||||||
| Founders advisory fees - related party | 189,877 | 16,270 | |||||||||||||||
Non-recurring expenses (1) | 2,934 | 947 | |||||||||||||||
| Acquisition costs | 12,526 | 828 | |||||||||||||||
| Stock-based compensation expense | 5,490 | 4,909 | |||||||||||||||
Purchase accounting impact - inventory step up (2) | 10,070 | — | |||||||||||||||
| Foreign currency gain | (2,554) | (3,255) | |||||||||||||||
Tax impact of non-GAAP adjustments (3) | (87,663) | (11,694) | |||||||||||||||
| Adjusted net income | $ | 68,605 | $ | 61,233 | |||||||||||||
| Shares used in computing GAAP Earnings Per Share (diluted) | 158,663,642 | 156,039,133 | |||||||||||||||
Options (4) | 7,110,289 | — | |||||||||||||||
Shares underlying Founders fixed advisory fees (5) | — | (7,071,183) | |||||||||||||||
Shares underlying Founders variable advisory fees (6) | — | — | |||||||||||||||
| Shares used in computing Adjusted Earnings Per Share (diluted) | 165,773,931 | 148,967,950 | |||||||||||||||
| GAAP (Loss) Earnings Per Share (diluted) | $ | (0.69) | $ | 0.16 | |||||||||||||
| Adjusted Earnings Per Share (diluted) | $ | 0.41 | $ | 0.41 | |||||||||||||
| ______________________________ | |||||||||||||||||
| (1) | For the six months ended June 30, 2026, $1.5 million was related to restructuring and other non-recurring costs and $1.4 million was related to litigation costs arising from a contractual dispute regarding control of the P2S5 facility, which is currently operated by Flexsys Chemical Company. For the six months ended June 30, 2025, $0.6 million was related to restructuring and other non-recurring costs and $0.4 million was related to the Redomiciliation Transaction. | ||||||||||||||||
| (2) | For the six months ended June 30, 2026, $10.1 million was primarily related to the impact of purchase accounting on the cost of inventory sold. The acquired inventory was recorded at fair value, resulting in a step-up in basis. | ||||||||||||||||
| (3) | The tax impact of non-GAAP adjustments reflects the total income tax expense commensurate with the non-GAAP measure of profitability. | ||||||||||||||||
| (4) | The Company adds back the dilutive impact of options if amounts were excluded for purposes of GAAP EPS due to a GAAP net loss during the period. | ||||||||||||||||
| (5) | As of June 30, 2026, a maximum of 2.4 million shares were issuable within 12 months under the Founders fixed advisory fee. | ||||||||||||||||
| (6) | Based on period end market prices as of June 30, 2026, a maximum of 6.1 million shares were issuable within 12 months under the Founders variable advisory fee. | ||||||||||||||||